Cognition Conversations

Episode 10: Studying the Patient-Caregiver Lived Experience in Dementia with Lewy Bodies

Featuring: Brendan Kelley, MD (moderator), UT Southwestern Medical Center, Professor and Clinical Vice Chair in the Department of Neurology Samantha K. Holden, MD, MS, FAAN, University of Colorado School of Medicine, Associate Professor of Neurology, Vice Chair for Outpatient Neurology Services Carla Preyer, Salon Owner, Inspirational Speaker, Care Partner to her Husband, Patrick Linda Szypula Ed.D., Science Teacher, Care Partner to her Husband, James Index: 0:00 Introduction 2:00 Caregiver Distress and Symptom Burden 16:14 Measuring Meaningful Changes in a Clinical Trial 22:09 Closing remarks

Episode 9: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Featuring: Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer James E. Galvin, MD, MPH, University of Miami, Director of the Comprehensive Center for Brain Health, Miller School of Medicine Lawrence S. Honig, MD, PhD, FAAN, Columbia University, Professor of Neurology, Irving Medical Center David Shprecher, D.O., Banner Sun Health Research Institute, Movement Disorder Director, Banner Sun Health Clinical Associate Professor, University of Arizona Index: 0:00 Introduction 0:45 Comparing Alzheimer’s disease and DLB 5:02 SHIMMER Design and Outcomes 10:22 Metrics for Success in a Signal-finding Study

Episode 8: Protecting the Synapse from Amyloid Toxicity in Alzheimer’s Disease

Featuring: Anthony Caggiano, M.D., Ph.D. (moderator) Cognition Therapeutics, Chief Medical Officer Mary Hamby, Ph.D. (moderator) Cognition Therapeutics, Vice President of Research Everard (Jort) Vijverberg, MD, PhD Alzheimer Center at Amsterdam University Medical Center, Neurologist and CNS Trial Specialist Tara Spires Jones, DPhil University of Edinburgh, Personal Chair of Neurodegeneration and Deputy Director of the Centre for Discovery Brain Sciences Index: 0:00 Introduction 3:49 Findings from SEQUEL 6:45 Clinical observations of CT1812 engagement 9:08 Proteomic evidence of CT1812 engagement 11:52 CT1812’s ongoing Phase 2 study

Episode 7: Quantitative EEG: Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease

Featuring: Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer Willem de Haan, M.D., Ph.D., Alzheimer Center at Amsterdam University Medical Center, Neurologist and Senior Researcher Philip Scheltens, M.D., EQT Life Sciences, Partner and Head of Dementia Fund, Former Director of the Alzheimer Center at Amsterdam University Medical Center Index: 0:00 Introduction 0:44 Rationale for the SEQUEL Study Design 2:10 EEG in neurodegenerative diseases 4:33 Findings from SEQUEL 9:52 Key Takeaways

Episode 6: Geographic Atrophy: New Strategies to Protect the Retina

Featuring: Anthony Caggiano, M.D., Ph.D., Chief Medical Officer, Cognition Therapeutics C. Gustavo De Moraes, M.D., Ph.D. (moderator), Chief Medical Officer, Ora (CRO), and Associate Professor of Clinical Ophthalmology, Columbia University Jeffrey S. Heier, M.D., Director of the Vitreoretinal Service & Retina Research, Ophthalmic Consultants of Boston Peter K. Kaiser, M.D., Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine